Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal; Docetaxel; Hormones; Prednisone

Criteria

Inclusion Criteria:

• Diagnosis of metastatic, progressive hormone refractory prostate cancer

• Adequate bone marrow, liver and kidney function

Exclusion Criteria:

• Previous treatment with chemotherapy